Inhibitors of C–X–C motif chemokine receptor 1 (CXCR1), the IL-8 receptor, and antagonistic TGFβ antibodies have been demonstrated to reduce cancer stem cell expansion and limit tumor relapse post therapy18,39. This evidence concerns the gene CXCR1 and neoplasm.